ADMA Biologics Inc

ADMA remains in a Stage 4 decline, characterized by a clear sequence of lower highs and lower lows with EMAs acting as resistance. Medium-term bias is bearish, but short-term price is range-bound under flat-to-declining EMAs and neutral indicators. We recommend deferring bearish execution and preparing to trim positions on rallies into the EMA/resistance zone.

• ↑Q1 Ascentive sales rose 28% YoY to $97.5M, driving growth
• ↑Gross margin expanded to 71%, underscoring strong profitability factors
• ↓Multiple securities-fraud suits allege channel stuffing, reputational risk